Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to pioneering tumor-activated immuno-oncology (I-O) therapies aimed at significantly improving outcomes for cancer patients. The company's name, Xilio, is derived from the Latin term 'ex nihilo,' meaning creation or big bang, symbolizing its innovative approach.
Xilio leverages its proprietary platform to develop a pipeline of novel, tumor-activated clinical and preclinical I-O molecules. These include engineered antibodies, cytokines, and chemokines, all designed to localize anti-tumor activity within the tumor microenvironment, thus optimizing the therapeutic index and minimizing systemic side effects.
Key Products and Developments:
- XTX202: An investigational tumor-activated, engineered IL-2 molecule designed to stimulate CD8+ effector T cells and natural killer (NK) cells without stimulating regulatory T cells. Recent Phase 1/2 data showed a 50% disease control rate at higher doses, and it is currently being evaluated in a Phase 2 trial for melanoma and renal cell carcinoma.
- XTX101: A tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is being evaluated in combination with atezolizumab in a Phase 1/2 clinical trial for advanced solid tumors.
- XTX301: An engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. XTX301 is in a Phase 1 clinical trial, and Xilio has recently entered into an exclusive license agreement with Gilead Sciences for its development.
Recent Achievements:
- XTX202 Phase 1 monotherapy dose-escalation success at a dose level of 4.0 mg/kg, with plans to explore combination therapy opportunities.
- The company announced a strategic partnership with Gilead Sciences to accelerate the development of XTX301.
- Financial results indicate that Xilio's existing cash and cash equivalents can fund operations into the second quarter of 2025, bolstered by recent private placements and upfront payments from strategic partnerships.
For more detailed information on Xilio Therapeutics and its pipeline of tumor-activated I-O therapies, visit www.xiliotx.com.
Rhea-AI Summary
Xilio Therapeutics, Inc. announced René Russo's participation in the 'Novel Immuno-Oncology' panel discussion at the TD Cowen 44th Annual Health Care Conference. The event will take place on March 4, 2024, at 10:30 am EST, with a live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.42%
Tags
-
Rhea-AI Summary
Xilio Therapeutics, Inc. announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The company focuses on discovering and developing tumor-activated immuno-oncology therapies for cancer patients. The event will be live webcasted and accessible through the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
-
Rhea-AI Summary
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company reporting encouraging preliminary safety data from the first three dose levels of XTX301, a tumor-activated IL-12, in patients with advanced solid tumors. The company has also initiated patient dosing in Phase 1/2 trial for XTX101 and plans to report Phase 2 trial data for XTX202 by the end of the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Xilio Therapeutics, Inc. (XLO) announced the initiation of enrollment for its Phase 1 clinical trial of XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab and reported updated monotherapy data from its ongoing Phase 1 clinical trial evaluating XTX101 in late-line patients with advanced and immuno-oncology (IO) refractory solid tumors. The data were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on December 7, 2023. The Phase 1 combination dose escalation is expected to support a planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC). The updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events, consistent with tumor-activated molecule design, and a 33% disease control rate across a range of late-line and IO refractory advanced solid tumors. The company also reported a confirmed partial response with XTX101 monotherapy in a patient with advanced PD-L1 negative NSCLC continued through 36 weeks, including complete resolution of liver metastases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
News
Rhea-AI Summary
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced pipeline progress and business updates, including the initial clinical validation of tumor-selective activation technology for XTX101 and XTX202. The company reported a 50% disease control rate at higher doses for XTX202 and plans to evaluate XTX202 as monotherapy. Xilio also anticipates reporting preliminary Phase 1 safety data for XTX301 in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.63%
Tags
-
Rhea-AI Summary
Xilio Therapeutics, a clinical-stage biotechnology company, announced initial safety and efficacy data from its Phase 1/2 clinical trial evaluating XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, in patients with advanced solid tumors. The trial showed a disease control rate of 50% at higher doses (≥2.8 mg/kg) and 31% across all dose levels. Treatment-related adverse events were primarily Grade 1-2, with no signs of vascular leak syndrome reported. Two patients continued treatment for more than 1 year. Xilio plans to evaluate XTX202 as a monotherapy in a Phase 2 trial for advanced melanoma and renal cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
Rhea-AI Summary
Xilio Therapeutics, Inc. will host an investor conference call and webcast on November 6, 2023, to review progress across its pipeline of tumor-activated molecules. The call will feature the presentation of Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, at the SITC 38th Annual Meeting. The webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
-
Rhea-AI Summary
Xilio Therapeutics to present preliminary data from Phase 1/2 clinical trial at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
-
Rhea-AI Summary
Xilio Therapeutics announces the promotion of Katarina Luptakova, M.D., to chief medical officer and Scott Coleman, Ph.D., to chief development officer. Martin Huber, M.D., will leave the company to pursue a CEO opportunity but will remain as an advisor. The promotions highlight the depth of Xilio's internal talent and its successful clinical development efforts. Luptakova brings extensive experience in clinical oncology drug development, while Coleman has a strong background in drug development and strategic thinking. Xilio's recent early clinical data shows promising results for its tumor-activated immuno-oncology therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
Rhea-AI Summary
Xilio Therapeutics CEO to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
The current stock price of Xilio Therapeutics (XLO) is $1.469 as of November 4, 2024.
What is the market cap of Xilio Therapeutics (XLO)?
The market cap of Xilio Therapeutics (XLO) is approximately 63.3M.
What is Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing tumor-activated immuno-oncology therapies to improve outcomes for cancer patients.
What does the name Xilio mean?
The name Xilio is derived from the Latin term 'ex nihilo,' which means creation or big bang, symbolizing the company's innovative approach.
What are the key products developed by Xilio?
Xilio's key products include XTX202 (engineered IL-2), XTX101 (anti-CTLA-4 antibody), and XTX301 (engineered IL-12).
What is the focus of Xilio's technology platform?
Xilio's technology platform focuses on developing tumor-activated I-O molecules that localize anti-tumor activity within the tumor microenvironment to optimize therapeutic index and reduce systemic side effects.
What recent achievements has Xilio reported?
Recent achievements include successful Phase 1 monotherapy dose-escalation for XTX202, a strategic partnership with Gilead Sciences for XTX301, and financial stability into the second quarter of 2025.
What is XTX202?
XTX202 is an investigational tumor-activated IL-2 molecule designed to stimulate CD8+ effector T cells and NK cells without stimulating regulatory T cells. It is in Phase 2 trials for melanoma and renal cell carcinoma.
What is XTX101?
XTX101 is a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is in Phase 1/2 trials for advanced solid tumors.
What is XTX301?
XTX301 is an engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. It is in a Phase 1 clinical trial.
How can I learn more about Xilio Therapeutics?
For more information on Xilio Therapeutics and its pipeline, visit their official website at www.xiliotx.com.
What are the financial prospects of Xilio Therapeutics?
Xilio Therapeutics reports that its current cash and cash equivalents are sufficient to fund its operations into the second quarter of 2025, supported by recent strategic partnerships and private placements.
Xilio Therapeutics, Inc.
Nasdaq:XLO
XLO Rankings
XLO Stock Data
63.29M
43.95M
40.93%
30.22%
0.24%
Biotechnology
Pharmaceutical Preparations
United States of America
WALTHAM